Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →MASLD in Pregnancy: Rising Prevalence and Adverse Maternal and Perinatal Outcomes in a National Cohort, 2016-2022.
Clinical takeawayIn pregnant patients with MASLD, consider heightened monitoring for hypertensive complications (aOR 1.88 vs no CLD), preterm birth (aOR 1.41 vs no CLD), and postpartum hemorrhage (aOR 1.33 vs no CLD), given the increased risk compared to pregnancies without chronic liver disease.
What it foundMASLD prevalence in pregnancy rose threefold from 45.7 to 141.6 cases per 100,000 pregnancies between 2016 and 2022, with higher odds of hypertensive complications (aOR 1.88 vs no CLD), preterm birth (aOR 1.41 vs no CLD), and postpartum hemorrhage (aOR 1.33 vs no CLD).
ContextConfirms and quantifies the rising prevalence of MASLD in pregnancy and its association with adverse maternal outcomes, extending prior evidence on MASLD's impact in this population. Findings apply specifically to pregnant women ≥20 weeks gestation with MASLD.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Grba MH … Gandhi S · Digestive Diseases and Sciences · IF 2.5 · PubMed ↗